Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug
Pharmaceuticals · 13.01.2025 · 18 (1) · 86
DOI: 10.3390/ph18010086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 13.01.2025. Verfasst von Clément Boisseillier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Orodispersible thin film (ODF) is an innovative dosage form that allows for adjustable dosing and improved patient compliance. It is administered by mouth, where it dissolves, making it suitable for children.
Objectives
The aim of the study was to develop and characterize an optimal ODF formulation containing equivalent hydrocortisone at 0.5 mg/cm2 using the solvent-casting method. A stability-indicating assay for the simultaneous quantification of hydrocortisone and hydrocortisone 21-hemissucinate (HMS) was developed. ODFs were characterized by organoleptic properties and by testing for uniformity of mass, content, stability, thickness, and dissolution.
Results
When optimized, ODF is thin, flexible, and transparent, making it suitable for production in hospital pharmacies using standard equipment. In contrast to the water-insoluble hydrocortisone, the HMS-loaded cast gel successfully satisfied the tests, including content uniformity. Disintegration appeared acceptable as compared to the commercial grade ondansetron ODF (Setofilm®). The physicochemical stability of the active ingredients (i.e., HMS, hydrocortisone) contained in the ODF at 0.5 mg/cm2 is demonstrated for at least 84 days at 23 °C.
Conclusion
The ODF formulated with the water-soluble hydrocortisone prodrug HMS allows accurate drug level to be achieved, thus opening up new opportunities for use in pediatric patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
- Service d'Endocrinologie, Diabétologie, Gynécologie Pédiatriques, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 Rue de Sèvres, F-75015 Paris, France.
- Institut Cochin, Inserm U1016, Université Paris Cité, F-75014 Paris, France.
- Institut Imagine, Inserm U1163, F-75015 Paris, France.
- Service Pharmacie, Institut Gustave Roussy, F-94800 Villejuif, France.
- Inserm UMRS 1144, Université Paris Cité, 4, Avenue de l'Observatoire, F-75006 Paris, France.
ORCID-Profile: Lucas Demange-Labriet, Dulanjalee Kariyawasam, Maxime Annereau, Arnaud Schweitzer-Chaput
Zitieren
APA
Boisseillier, C., Demange-Labriet, L., Kariyawasam, D., Marchadour, P., Fauqueur, A. S., Annereau, M., Denis, L., Cotteret, C., Cisternino, S., & Schweitzer-Chaput, A. (2025). Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug. Pharmaceuticals, 18(1), 86. https://doi.org/10.3390/ph18010086
Vancouver
Boisseillier C, Demange-Labriet L, Kariyawasam D, Marchadour P, Fauqueur AS, Annereau M, et al. Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug. Pharmaceuticals. 2025;18(1):86. doi:10.3390/ph18010086
BibTeX
@article{Boisseillier2025,
author = {Boisseillier, Clément and Demange-Labriet, Lucas and Kariyawasam, Dulanjalee and Marchadour, Pauline and Fauqueur, Anne-Sophie and Annereau, Maxime and Denis, Lucas and Cotteret, Camille and Cisternino, Salvatore and Schweitzer-Chaput, Arnaud},
title = {Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {1},
pages = {86},
doi = {10.3390/ph18010086}
}
EUVIMED